Adiponectin: A risk biomarker and attractive target for chemoprevention

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages 124-126

  Fabian, Carol J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANTILIPEMIC AGENT; AROMATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FENRETINIDE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE LKB1; PROTEIN P53; RALOXIFENE; RETINOID X RECEPTOR GAMMA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; APOPTOSIS; BARIATRIC SURGERY; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL SECRETION; CHEMOPROPHYLAXIS; CONCENTRATION (PARAMETERS); CORONARY ARTERY DISEASE; EDITORIAL; ENERGY METABOLISM; ENZYME ACTIVITY; FOLLOW UP; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAEPITHELIAL NEOPLASIA; METABOLIC DISORDER; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PARACRINE SIGNALING; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; RISK ASSESSMENT; RISK REDUCTION; WEIGHT REDUCTION;

ADIPONECTIN; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; FEMALE; FENRETINIDE; HUMANS; PREMENOPAUSE; TAMOXIFEN;

EID: 84855590139     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.5500     Document Type: Editorial

References (35)

1. Macis D, Gandini S, Guerrieri-Gonzaga A, et al: Prognostic effect of circulating adiponectin in a randomized 2 - 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 30:151-157, 2012
2. Barb D, Williams CJ, Neuwirth AK, et al: Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr 86:s858-s866, 2007
3. Körner A, Pazaitou-Panayiotou K, Kelesidis T, et al: Total and high-molecular- weight adiponectin in breast cancer: In vitro and in vivo studies. J Clin Endocrinol Metab 92:1041-1048, 2007 (Pubitemid 46465681)
4. Duggan C, Irwin ML, Xiao L, et al: Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29:32-39, 2011
5. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al: Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27:3749-3756, 2009
6. Ryan AS, Berman DM, Nicklas BJ, et al: Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 26:2383-2388, 2003 (Pubitemid 36993330)
7. Vona-Davis L, Rose DP: Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14:189-206, 2007 (Pubitemid 47242622)
8. Kern PA, Di Gregorio GB, Lu T, et al: Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52:1779-1785, 2003 (Pubitemid 36792470)
9. Wang Y, Lam JB, Lam KS, et al: Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462-11470, 2006 (Pubitemid 46009979)
10. Wang Y, Lam KS, Xu A: Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 17:280-282, 2007 (Pubitemid 46639924)
11. Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, et al: Involvement of adiponectin and leptin in breast cancer: Clinical and in vitro studies. Endocr Relat Cancer 16:1197-1210, 2009
12. Hattori Y, Nakano Y, Hattori S, et al: High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett 582:1719-1724, 2008
13. Rahal OM, Simmen RC: Paracrine-acting adiponectin promotes mammary epithelial differentiation and synergizes with genistein to enhance transcriptional response to estrogen receptor β signaling. Endocrinology 152:3409-3421, 2011
14. Vona-Davis L, Rose DP: Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 20:193-201, 2009
15. Grossmann ME, Ray A, Nkhata KJ, et al: Obesity and breast cancer: Status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 29:641-653, 2010
16. Weiss EP, Racette SB, Villareal DT, et al: Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: A randomized controlled trial. Am J Clin Nutr 84:1033-1042, 2006 (Pubitemid 44730373)
17. Ryan AS, Nicklas BJ, Berman DM, et al: Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord 27:1066-1071, 2003 (Pubitemid 37059612)
18. Christou NV, Lieberman M, Sampalis F, et al: Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis 4:691-695, 2008
19. Sjöström L, Gummesson A, Sjöström CD, et al: Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study) - A prospective, controlled intervention trial. Lancet Oncol 10:653-662, 2009
20. Kelly KR, Blaszczak A, Haus JM, et al: A 7-day exercise program increases high molecular weight adiponectin in obese adults. Med Sci Sports Exerc [epub ahead of print on June 16, 2011]
21. Moghadasi M, Mohebbi H, Rahmani-Nia F, et al: High-intensity endurance training improves adiponectin mRNA and plasma concentrations. Eur J Appl Physiol [epub ahead of print on July 17, 2011]
22. Rokling-Andersen MH, Reseland JE, Veierød MB, et al: Effects of long-term exercise and diet intervention on plasma adipokine concentrations. Am J Clin Nutr 86:1293-1301, 2007 (Pubitemid 350126230)
23. Friedenreich CM, Neilson HK, Woolcott CG, et al: Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women. Endocr Relat Cancer 18:357-369, 2011
24. Westerink J, Visseren FL: Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 10:13, 2011
25. Hanefeld M, Pfutzner A, Forst T, et al: Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: The PIOCOMB study. Cardiovasc Diabetol 10:65, 2011
26. Wanders D, Plaisance EP, Judd RL: Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes 1:116-128, 2010
27. Banga A, Unal R, Tripathi P, et al: Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 296:E480-E489, 2009
28. Oki K, Koide J, Nakanishi S, et al: Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J 54:431-435, 2007 (Pubitemid 47105431)
29. Storka A, Vojtassakova E, Mueller M, et al: Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 38:820-826, 2008
30. Nakamura T, Kawachi K, Saito Y, et al: Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J 50:501-512, 2009
31. Aggarwal BB: Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30:173-199, 2010
32. Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, et al: Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric 11:155-165, 2008 (Pubitemid 351451118)
33. Aguilar-Salinas CA, García EG, Robles L, et al: High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93:4075-4079, 2008
34. Inoue T, Kotooka N, Morooka T, et al: High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 100:569-574, 2007 (Pubitemid 47223129)
35. Grossmann ME, Ray A, Dogan S, et al: Balance of adiponectin and leptin modulates breast cancer cell growth. Cell Res 18:1154-1156, 2008